RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

#EULAR2021 #EULAR21 #eular #spondyloarthritis I have always thought we named nr-axSPA wrongly - Tends to trivialise its gravity and importance Shouldn’t it be our goal to diagnose all SpA at the nr-axSPA stage @deodhara @NigilHaroon https://t.co/zwKI1o9WcO

#EULAR2021: AxSpA patients with greater patient-reported pain and spinal pain relative to axPsA patients among real-world patients in CorEVitas' Psa/Spa observational Registry per Dr. Mease's oral abstract presentation. @RheumNow https://t.co/YEdhd7x6cb

#EULAR2021 - Key points from Dr. Mease's oral abstract: ⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD ⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts ⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status @Rheumnow

#EULAR2021: AxSpA patients more likely to experience IBD and uveitis whereas axPsA more likely to experience dactylitis and enthesitis per Dr. Philip Mease's study among real-world patients in CorEVitas' Psa/Spa Registry. @RheumNow https://t.co/g2m5fylFJj

#EULAR2021: SpA pts w/ predominant axial phenotype tended to be HLAB27+ & have uveitis whereas those w/ predom peripheral phenotype tended to have arthritis, dactylitis, or psoriasis & fit a clinical dx of axSpA & psSpa (incl psA) respectively per this observat study. @RheumNow https://t.co/E5UTbc6Sqb

#EULAR2021 bDMARD and TNF-i naive patients w/ r-axSpA without evidence of objective inflammation (normal CRP & MRI ) showed ASA40 response w/ ixekizumab @RheumNow https://t.co/5KT8A81auq

#OP0089 Do you know the pain catastrophizing score #PCS ? Cross-sectional study of 1199 #RA, #PsA & #ax-SpA patients: Low PCS were more often in remission as high PCS in RA & ax-SpA. PCS was associated with remission rates in RA and ax-SpA, but not in PsA #EULAR2021 @RheumNow https://t.co/MYiLmPPbDN

#EULAR2021: In India, some of the JAKi are costing less than $30/mo per a EULAR participant! Dr. Filip van den Bosch does not recommend using tofacitinib as a diagnostic tool for SpA over NSAIDs even if it is so cheap. @RheumNow

#EULAR2021: Dr. Filip van den Bosch recommends the "DEER" treatment approach for SpA: Dedicated Empathic and Educated Rheumatologist! @RheumNow https://t.co/W0jbGXk7q8

#OP0049 corevitas observational registry: ax-SpA patients showed younger age, more males, greater spinal pain, more exposure to cs- or bDMARD but similar fatigue and work impairment compared to ax-PsA #EULAR2021 @RheumNow

#EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been much evolution in efficacy of therapy for SpA in the past 20 yrs. This suggests we haven't been looking at the right endpoint in measuring efficacy! MDA instead! @RheumNow https://t.co/E61yb97CRN

#Eular2021: There is no diagnostic criteria for nr-AxSpA, but there is a diagnostic approach that entails collecting clinical information and imaging to visualize inflammation or post-inflammatory changes of the axial skeleton. @RheumNow

#Eular2021: Do you start a bDMARD for nr-AxSpa without objective evidence of inflammation (elevated CRP, negative structural damage on MRI)? @RheumNow